Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Sang Hyun Lee; Kyuhwan Kim; Eunyoung Lee; Kyungmin Lee; Kyeong Hwan Ahn; Hansom Park; Yelim Kim; Soeun Shin; Sang Youl Jeon; Yongki Hwang; Dong Hyuck Ahn; Yong Jun Kwon; Seok Whan Moon; Mi Hyoung Moon; Kyung Soo Kim; Kwanyong Hyun; Tae Jung Kim; Yeoun Eun Sung; Joon Young Choi; Chan Kwon Park; Sung Won Kim; Chang Dong Yeo; Hyun Jung Sohn; You Seok Hyun; Tai Gyu Kim; Bosung Ku; Jeong Uk Lim; Seung Joon Kim

doi:10.1038/s41698-024-00609-7

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Sang Hyun Lee, Kyuhwan Kim, Eunyoung Lee, Kyungmin Lee, Kyeong Hwan Ahn, Hansom Park, Yelim Kim, Soeun Shin, Sang Youl Jeon, Yongki Hwang, Dong Hyuck Ahn, Yong Jun Kwon, Seok Whan Moon, Mi Hyoung Moon, Kyung Soo Kim, Kwanyong Hyun, Tae Jung Kim, Yeoun Eun Sung, Joon Young Choi, Chan Kwon ParkSung Won Kim, Chang Dong Yeo, Hyun Jung Sohn, You Seok Hyun, Tai Gyu Kim, Bosung Ku^*, Jeong Uk Lim^*, Seung Joon Kim^*

^*Corresponding author for this work

Precision Medicine Technology

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This study focused on patients with advanced EGFR-mutated non-small cell lung cancer and employed a cancer organoid-based diagnosis reactivity prediction (CODRP)-based precision oncology platform to assess the efficacy of EGFR inhibitor treatments. CODRP was employed to evaluate EGFR-tyrosine kinase inhibitors (TKI) drug sensitivity. The results were compared to those obtained using area under the curve index. This study validated this index by testing lung cancer-derived organoids in 14 patients with lung cancer. The CODRP index-based drug sensitivity test reliably classified patient responses to EGFR-TKI treatment within a clinically suitable 10-day timeline, which aligned with clinical drug treatment responses. This approach is promising for predicting and analyzing the efficacy of anticancer, ultimately contributing to the development of a precision medicine platform.

Original language	English
Article number	111
Journal	npj Precision Oncology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/s41698-024-00609-7
Publication status	Published - Dec 2024

Access to Document

10.1038/s41698-024-00609-7Licence: CC BY

Cite this

Lee, S. H., Kim, K., Lee, E., Lee, K., Ahn, K. H., Park, H., Kim, Y., Shin, S., Jeon, S. Y., Hwang, Y., Ahn, D. H., Kwon, Y. J., Moon, S. W., Moon, M. H., Kim, K. S., Hyun, K., Kim, T. J., Sung, Y. E., Choi, J. Y., ... Kim, S. J. (2024). Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion. npj Precision Oncology, 8(1), Article 111. https://doi.org/10.1038/s41698-024-00609-7

@article{2f59265e8ee5463abcab3b85a85d5c0e,

title = "Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion",

abstract = "Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This study focused on patients with advanced EGFR-mutated non-small cell lung cancer and employed a cancer organoid-based diagnosis reactivity prediction (CODRP)-based precision oncology platform to assess the efficacy of EGFR inhibitor treatments. CODRP was employed to evaluate EGFR-tyrosine kinase inhibitors (TKI) drug sensitivity. The results were compared to those obtained using area under the curve index. This study validated this index by testing lung cancer-derived organoids in 14 patients with lung cancer. The CODRP index-based drug sensitivity test reliably classified patient responses to EGFR-TKI treatment within a clinically suitable 10-day timeline, which aligned with clinical drug treatment responses. This approach is promising for predicting and analyzing the efficacy of anticancer, ultimately contributing to the development of a precision medicine platform.",

author = "Lee, {Sang Hyun} and Kyuhwan Kim and Eunyoung Lee and Kyungmin Lee and Ahn, {Kyeong Hwan} and Hansom Park and Yelim Kim and Soeun Shin and Jeon, {Sang Youl} and Yongki Hwang and Ahn, {Dong Hyuck} and Kwon, {Yong Jun} and Moon, {Seok Whan} and Moon, {Mi Hyoung} and Kim, {Kyung Soo} and Kwanyong Hyun and Kim, {Tae Jung} and Sung, {Yeoun Eun} and Choi, {Joon Young} and Park, {Chan Kwon} and Kim, {Sung Won} and Yeo, {Chang Dong} and Sohn, {Hyun Jung} and Hyun, {You Seok} and Kim, {Tai Gyu} and Bosung Ku and Lim, {Jeong Uk} and Kim, {Seung Joon}",

note = "Acknowledgements This study was supported by a grant (C390000) from the Korea Basic Science Institute and by the Ministry of Science and ICT, (2024-22030007-00) and Commercialization Promotion Agency for R&D Outcomes (COMPA). Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41698-024-00609-7",

language = "English",

volume = "8",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Springer Nature",

number = "1",

}

Lee, SH, Kim, K, Lee, E, Lee, K, Ahn, KH, Park, H, Kim, Y, Shin, S, Jeon, SY, Hwang, Y, Ahn, DH, Kwon, YJ, Moon, SW, Moon, MH, Kim, KS, Hyun, K, Kim, TJ, Sung, YE, Choi, JY, Park, CK, Kim, SW, Yeo, CD, Sohn, HJ, Hyun, YS, Kim, TG, Ku, B, Lim, JU & Kim, SJ 2024, 'Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion', npj Precision Oncology, vol. 8, no. 1, 111. https://doi.org/10.1038/s41698-024-00609-7

TY - JOUR

T1 - Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

AU - Lee, Sang Hyun

AU - Kim, Kyuhwan

AU - Lee, Eunyoung

AU - Lee, Kyungmin

AU - Ahn, Kyeong Hwan

AU - Park, Hansom

AU - Kim, Yelim

AU - Shin, Soeun

AU - Jeon, Sang Youl

AU - Hwang, Yongki

AU - Ahn, Dong Hyuck

AU - Kwon, Yong Jun

AU - Moon, Seok Whan

AU - Moon, Mi Hyoung

AU - Kim, Kyung Soo

AU - Hyun, Kwanyong

AU - Kim, Tae Jung

AU - Sung, Yeoun Eun

AU - Choi, Joon Young

AU - Park, Chan Kwon

AU - Kim, Sung Won

AU - Yeo, Chang Dong

AU - Sohn, Hyun Jung

AU - Hyun, You Seok

AU - Kim, Tai Gyu

AU - Ku, Bosung

AU - Lim, Jeong Uk

AU - Kim, Seung Joon

N1 - Acknowledgements This study was supported by a grant (C390000) from the Korea Basic Science Institute and by the Ministry of Science and ICT, (2024-22030007-00) and Commercialization Promotion Agency for R&D Outcomes (COMPA). Publisher Copyright: © The Author(s) 2024.

PY - 2024/12

Y1 - 2024/12

N2 - Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This study focused on patients with advanced EGFR-mutated non-small cell lung cancer and employed a cancer organoid-based diagnosis reactivity prediction (CODRP)-based precision oncology platform to assess the efficacy of EGFR inhibitor treatments. CODRP was employed to evaluate EGFR-tyrosine kinase inhibitors (TKI) drug sensitivity. The results were compared to those obtained using area under the curve index. This study validated this index by testing lung cancer-derived organoids in 14 patients with lung cancer. The CODRP index-based drug sensitivity test reliably classified patient responses to EGFR-TKI treatment within a clinically suitable 10-day timeline, which aligned with clinical drug treatment responses. This approach is promising for predicting and analyzing the efficacy of anticancer, ultimately contributing to the development of a precision medicine platform.

AB - Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This study focused on patients with advanced EGFR-mutated non-small cell lung cancer and employed a cancer organoid-based diagnosis reactivity prediction (CODRP)-based precision oncology platform to assess the efficacy of EGFR inhibitor treatments. CODRP was employed to evaluate EGFR-tyrosine kinase inhibitors (TKI) drug sensitivity. The results were compared to those obtained using area under the curve index. This study validated this index by testing lung cancer-derived organoids in 14 patients with lung cancer. The CODRP index-based drug sensitivity test reliably classified patient responses to EGFR-TKI treatment within a clinically suitable 10-day timeline, which aligned with clinical drug treatment responses. This approach is promising for predicting and analyzing the efficacy of anticancer, ultimately contributing to the development of a precision medicine platform.

UR - http://www.scopus.com/inward/record.url?scp=85193919649&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/38773241

U2 - 10.1038/s41698-024-00609-7

DO - 10.1038/s41698-024-00609-7

M3 - Article

C2 - https://pubmed.ncbi.nlm.nih.gov/38773241/

AN - SCOPUS:85193919649

SN - 2397-768X

VL - 8

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 111

ER -

Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion

Abstract

Access to Document

Other files and links

Fingerprint

Cite this